Insulin and semaglutide in one pen: what the Anvisa approval means for people with diabetes

What the COMBINE trial program measured

The COMBINE program includes three phase 3 studies, known as COMBINE 1, 2, and 3. Each one is registered on ClinicalTrials.gov, where you can look up eligibility criteria, outcomes, and status. The populations differ. COMBINE 1 enrolled people who had not used insulin before. COMBINE 2 enrolled people who were already using a GLP-1 receptor agonist. COMBINE 3 enrolled people who were already on basal insulin. Confirm these criteria in the registry entries and in the published papers, because summaries tend to simplify them.

The primary outcome is the change in HbA1c, the blood marker that reflects average glucose over roughly the previous two to three months. The time point and the comparator arms matter as much as the figure itself. The papers compare the combination with insulin icodec alone and with semaglutide alone. Avoid quoting numbers from press releases, which can round results or skip the confidence intervals that show how precise an estimate is. Find the peer-reviewed publications on PubMed and quote from the tables there.

Secondary outcomes typically include body weight, rates of hypoglycemia, and gastrointestinal events such as nausea. These are the outcomes people notice in daily life, and this is where the two components can behave differently. Weight and gastrointestinal effects tend to follow semaglutide, while hypoglycemia tends to follow insulin, but check each point in the published tables rather than trust that rule of thumb.

Several questions remain open. The COMBINE trials were designed around glucose control, so they can't settle long-term cardiovascular questions on their own. Real-world adherence is another gap, since trials usually involve closer follow-up than everyday life. And people outside the inclusion criteria, such as those with very different kidney function or many other medicines, are not the population these studies were built to describe.

Who the combination is for and who should avoid it

The approved indication in Brazil is written in the leaflet. It states the type of diabetes, the minimum age, and the conditions of use. Don't treat any use outside that indication as safe just because someone else does it. If your situation falls outside the leaflet, ask your doctor whether another option fits better.

Semaglutide carries a warning about medullary thyroid carcinoma. People with a personal or family history of this tumor, or with multiple endocrine neoplasia syndrome type 2, should not use it. The warning matters during screening because a family history question is easy to skip in a busy visit, and missing it has serious consequences. Check the contraindication and the warning text in the current leaflet.

Other cautions include a history of pancreatitis, kidney disease, pregnancy, and breastfeeding. Each has its own section in the leaflet, and labeling can change over time. Don't extend general statements about GLP-1 medicines to this specific pen without reading the document in front of you.

Some situations need an in-person assessment before anyone starts. A common example is a sulfonylurea. Combined with insulin, sulfonylureas raise the risk of hypoglycemia, so your doctor may need to adjust or stop that medicine. That decision depends on blood tests, your full medication list, and how you respond to treatment, none of which a leaflet can assess for you.

Daily routine, access and questions for the endocrinologist

The main practical change is the schedule. Instead of a daily basal insulin injection, the combination is taken once a week. That can simplify travel, work, and memory, but a missed dose or a change of injection day needs a clear plan. Follow the leaflet on priming, storage, missed doses, and day changes. Don't invent your own timeframes, because the leaflet's rules are the ones that apply to this product.

If you're building a routine around weekly injections, PeptPro's notes on building an injection routine offer practical ideas, but they don't replace the instructions that come with your pen. Write down your injection day, keep the pen in the storage conditions the leaflet describes, and set a reminder that actually works for you.

Access depends on systems that change over time. Check whether the product appears in the CMED price list, the government chamber that regulates maximum prices for medicines in Brazil. Then ask your health plan directly how it handles coverage, since the ANS reference list covers procedures and health events. For the public system, check availability at your local health unit. These details change, so verify them on the day you read this post.

Bring a short list of questions to your endocrinologist. Here are four to start:

• Which blood tests and monitoring schedule should I follow once I start this combination?
• How should you adjust my other diabetes medicines, especially any sulfonylurea or my current basal insulin?
• What should I do if I notice shaking, sweating, confusion, or a racing heartbeat?
• How will we know whether the combination is working for me, and when would we switch to something else?

Checking sources and where to go from here

Be cautious with sellers offering insulin or semaglutide without a prescription, especially on unverified websites or messaging apps. Counterfeit and unregulated products are a real risk. Read the registration number on the package and confirm it in Anvisa's database. If the product name or number doesn't match, don't use it.

Compare information from several sources before you decide. The leaflet is the baseline, the regulator's database shows the official status, and your doctor knows your history. Use PeptPro's source-checking guide to build a simple checklist for reading medical claims, and bring that checklist to your next appointment. Also keep in mind that approval status varies by country. EMA and FDA listings are useful for comparison, but they don't establish approval in Brazil.

Our earlier posts on oral versus pen semaglutide and on weight regain after stopping GLP-1 medicines give useful context, though they answer different questions than this one.

The combination may help with glucose control for people who fit the approved indication, and it may simplify the weekly routine for some. It is not a cure for diabetes, and it doesn't replace monitoring, diet, physical activity, or follow-up. The right choice depends on an individual assessment, and that assessment belongs with your doctor.

FAQ

Is the insulin and semaglutide pen the same as taking two separate injections?

The active ingredients are the same, but the device and the schedule differ. Both medicines are given together once a week in a fixed ratio. Dosing still follows the leaflet, so read the product's instructions before switching.

Can anyone with diabetes use this combination?

No. The approved use is described in the leaflet, including the type of diabetes and the minimum age. Anyone outside that indication should talk to a doctor before considering it.

What should I do if I miss my weekly dose?

Follow the missed-dose instructions in the leaflet, because the rules for this product are specific. Don't double up or create your own timeframe. If you're unsure, call your doctor or pharmacist.

How can I confirm that a pen sold to me is registered in Brazil?

Check the registration number printed on the package against Anvisa's public consultation portal. Buy only from licensed pharmacies, and be wary of offers that skip the prescription or come from unverified sellers.

Sources

• Anvisa: bulário eletrônico e consultas de medicamentos
• Anvisa: Agência Nacional de Vigilância Sanitária
• ClinicalTrials.gov: public registry of clinical studies
• PubMed: peer-reviewed publications on the COMBINE trials of insulin icodec and semaglutide
• European Medicines Agency: medicines database
• U.S. Food and Drug Administration: drugs
• CMED: Câmara de Regulação do Mercado de Medicamentos
• ANS: Agência Nacional de Saúde Suplementar